Purpose: The incidence of localized prostate cancer has decreased with shifts in prostate cancer screening. While recent population based studies demonstrated a stable incidence of locoregional prostate cancer, they categorized organ confined, extraprostatic and lymph node positive disease together. However, to our knowledge the contemporary incidence of prostate cancer with pelvic lymph node metastases remains unknown. Materials and Methods: We used SEER (Surveillance, Epidemiology and End Results) data from 2004 to 2014 to identify men diagnosed with prostate cancer. We analyzed trends in the age standardized prostate cancer incidence by stage. The impact of disease extent on mortality was assessed by adjusted Cox proportional hazard analysis. Results: During the study period the annual incidence of nonmetastatic prostate cancer decreased from 5,119.1 to 2,931.9 per million men (IR 0.57, 95% CI 0.56e0.58, p <0.01) while the incidence of pelvic lymph node metastases increased from 54.1 to 79.5 per million men (IR 1.47, 95% CI 1.33e1.62, p <0.01). The incidence of distant metastases in men 75 years old or older reached a nadir in 2011 compared to 2004 (IR 0.81, 95% CI 0.74e0.90, p <0.01) and it increased in 2012 compared to 2011 (IR 1.13, 95% CI 1.02e1.24, p <0.05). The risk of cancer specific mortality significantly increased in men diagnosed with pelvic lymph node metastases (HR 4.5, 95% CI 4.2e4.9, p <0.01) and distant metastases (HR 21.9, 95% CI 21.2e22.7, p <0.01) compared to men with nonmetastatic disease. Conclusions: The incidence of pelvic lymph node metastases is increasing coincident with a decline in the detection of localized disease. Whether this portends an increase in the burden of advanced disease or simply reflects decreased lead time remains unclear. However, this should be monitored closely as the increase in N1 disease reflects an increase in incurable prostate cancer at diagnosis.
THE last decade was characterized by major shifts in prostate cancer epidemiology.
1e4 The prostate cancer incidence decreased from 175 to 100/100,000 men from 2007 to 2014 5 with a decrease in the incidence of local/regional prostate cancer. 2, 6, 7 Concurrent with this trend we Accepted for publication December 16, 2017 . No direct or indirect commercial incentive associated with publishing this article.
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1510 j www.jurology.com 0022-5347/18/1996-1510/0 THE JOURNAL OF UROLOGY reported that the decrease in localized disease detection was accompanied by an increase in the incidence of distant metastases in men older than 75 years following a nadir in 2011. 6 Others confirmed these findings. 2 Using SEER data we also found that the proportion of men with PLNM at radical prostatectomy is increasing. 6, 8 However, this may be secondary to selection bias in the performance of radical prostatectomy for higher risk features as up to 50% of men with low risk features now elect active surveillance. 9 In this study we used the most recent update of SEER through 2014 to examine temporal changes in the incidence of nonmetastatic disease, PLNM and distant metastases. In addition, we studied PCSM in men with nonmetastatic disease and pelvic lymph node metastases to determine the potential consequences of an increase in nonlocalized disease.
METHODS

Study Population
The SEER program of NCI (National Cancer Institute) captures a representative sample of 28% of the American population. 10 We identified 573,669 men 50 years old or older who were diagnosed with pathologically confirmed prostate cancer from 2004 to 2014 to examine the incidence by SEER Collaborative Stage with time. Only the 475,153 men with prostate cancer as the only malignancy were included in mortality analysis to avoid potential confounding due to competing cancer specific mortality. Additionally, men with missing stage and missing survival time were excluded, resulting in 443,000 men available for analysis. Incident prostate cancers were categorized into 3 groups by disease extent at diagnosis, including group 1dnonmetastatic disease (T1N0M0, T2N0M0, T3N0M0 and T4N0M0), 2dPLNM (N1M0) and 3ddistant metastasis (M1). 
Independent Variables
Outcomes and Statistical Analysis
We evaluated the yearly and quarterly age adjusted incidences of prostate cancer per million men standardized to the 2000 United States Census population with time. The quarterly incidence was assessed graphically and a linear model or a restricted cubic spline model was fitted based on the Akaike information criterion. A restricted cubic splines model was chosen to provide a flexible description of the nonlinear relationship when linearity was inappropriate. 11, 12 In addition, IRRs by year were calculated to evaluate relative changes in incidence to the beginning of the study period in 2004 and between each consecutive year. To account for missing values in TNM stage the quarterly incidence was derived by applying the proportion of each disease stage to the total number of men diagnosed with prostate cancer.
Sensitivity analysis was done to impute missing values with the clinical range of each cancer group. 13e15 We performed a subanalysis to account for potential detection bias secondary to increasing performance of prostatectomy in patients at high risk. The proportion of patients with PLNM who did and did not undergo prostatectomy was assessed by the Cochran-Armitage trend test.
Among men who had only prostate cancer we compared demographic characteristics, overall mortality and PCSM among those diagnosed with nonmetastatic disease, PLNM and distant metastases. Differences were evaluated using the percent of event count, the chi-square test for categorical variables and means, and the KruskalWallis test for continuous variables.
Kaplan-Meier curves were constructed to visualize unadjusted overall mortality and PCSM. Cox regression was used to determine the HR of PCSM adjusting for year of diagnosis, age at diagnosis, race/ethnicity, tumor grade and pathology findings. Men with missing survival time were excluded from survival analysis. Statistical Median followup was 4.9 (IQR 2.5e7.5), 3.6 (IQR 1.5e6.2) and 1.6 years (IQR 0.8e3.2) for nonmetastatic disease, PLNM and distant metastasis, respectively. On adjusted analyses among men 50 years old or older PLNM was associated with worse PCSM than nonmetastatic disease (HR.5, 95% CI 4.2e4.9, p <0.01, table 4). Distant metastases were associated with worse PCSM compared to nonmetastatic disease (HR 21.9, 95% CI 21.2e22.7, p <0.01). Among men 75 years old or older the HR of PLNM and distant metastasis compared to nonmetastatic disease was 2.9 (95% CI 2.4e3.5, p <0.01) while for PCSM it was 10.7 (95% CI 10.1e11.3, p <0.01). Figure 2 shows survival by stage at diagnosis.
DISCUSSION
We report that the incidence of PLNM has been increasing in the last decade, particularly in men 75 years old or older, in whom the incidence has more than doubled. This is notable because of the coincident decrease in prostate cancer screening, detection of localized disease and treatment. 7, 16, 17 Despite an overall decrease in the incidence of prostate cancer the increase in PLNM raises concern for an increase in disease severity at presentation in the current era, which could portend decreased disease specific survival.
These results are more striking when considering 2 concurrent trends which would tend to reduce PLNM detection. 1) Pelvic lymph node dissection during radical prostatectomy has decreased in recent years, coincident with the increased performance of minimally invasive surgical approaches. 17 2) This coincides with recommendations against lymph node dissection for low risk features at diagnosis. 18 These factors would tend to bias our results toward the null.
Alternatively the increased incidence of PLNM may be secondary to detection bias which is surgery or imaging based. To that end we performed a sensitivity analysis using SEER-Medicare data during the study period and found low and unchanging utilization of positron emission tomography-computerized tomography. 19 Pelvic imaging is also under performed in men with high risk disease, likely resulting in underestimation of the true incidence of PLNM. 20 Additionally, recent studies demonstrated that the rate of surgery of high risk disease has not increased in men older than 75 years, in whom the increased PLNM incidence is most pronounced. 9 Furthermore, our supplemental analysis, which was stratified by initial treatment, demonstrated an increase in PLNM even in men who had not undergone prostatectomy.
According to the classic Halstedian model of cancer progression an increased incidence of lymph Mean AE SD* node metastases may be the first indication of an increased burden of advanced disease. 21 Moreover, this incurable pattern of stepwise cancer spread is thought to be containable by early detection. 21 While there may be other contributing factors, the progression of undetected localized disease is a plausible explanation of this finding. However, we note that changes in disease characteristics at diagnosis do not necessarily imply that earlier detection or treatment would be beneficial or could have prevented disease progression. Furthermore, we cannot rule out that other epidemiological trends may have contributed to our findings. For instance, obesity, which increased during the study period in the United States, has been linked to more aggressive prostate cancer. 22, 23 Consistent with prior studies, 24e26 our contemporary assessment of the impact of stage at diagnosis of survival demonstrates that PLNM carries a 4.5-fold higher risk of PCSM compared to nonmetastatic disease. Although the risk of PCSM conferred by PLNM is lower in men who are 75 years old or older, it remains significant and threefold higher than the risk of nonmetastatic disease.
It is important to note that lead time bias may have significantly contributed to these findings, leading to a perceived decrease in survival following diagnosis solely due to men being diagnosed later in the disease process. However, interestingly men with PLNM were younger than those diagnosed with nonmetastatic disease and so they faced reduced overall survival, mirroring prior findings.
Clinically PLNM is a distinct entity with guidelines recommending androgen deprivation therapy based on level 1 evidence and some studies suggesting that these men also benefit from radiotherapy. 24, 27 In these men androgen deprivation therapy is associated with significant morbidity, including hot flashes, sexual dysfunction, osteoporosis, clinical fractures, cardiovascular events, obesity and insulin resistance. 28 Indeed, the morbidity of metastatic disease combined with the prolonged clinical course of prostate cancer has led to the recommendation that metastasis should be used as a new primary end point of prostate cancer clinical trials. 29 Our findings must be interpreted in the context of the study design. 1) The increased incidence of PLNM may be related to decreased prostate cancer screening. However, the implications of this association are unclear as an increased incidence of advanced disease at diagnosis would be expected with decreased detection of localized disease. It may not reflect an increased overall burden of advanced disease or imply a benefit to earlier detection. 2) Other concurrent trends in imaging, management and epidemiology may have contributed to our findings, as discussed. 3) We analyzed the most contemporary data to provide a current analysis of temporal variations. This limited our median followup, potentially underestimating the impact of PLNM and distant metastasis on PCSM.
CONCLUSIONS
The incidence of PLNM in the United States is increasing. Given the distinct clinical course and prognosis of PLNM compared to other disease stages, our findings warrant continued monitoring and observation.
